Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.

Trial Details

NCT ID
NCT04698252
Phase
PHASE2
Sponsor
Instituto do Cancer do Estado de São Paulo
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • Radiotherapy
  • Surgery
  • Radiofrequency ablation
Locations (sample)
  • São Paulo, São Paulo, Brazil|-23.5475,-46.63611

Key Eligibility Criteria

  • Female sex
  • ≥ 18 years of age
  • Histologically confirmed invasive breast cancer, with oligometastatic disease defined as one of the following criteria: 1) One to four bone lesions…
  • Oligometastatic sites amenable to treatment with a local therapy modality, including surgical resection, stereotactic radiotherapy, or radiofrequen…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →